Anti-tumor constituents from Paris polyphylla var. yunnanensis.
- Author:
Yu WANG
1
;
Yan-jun ZHANG
;
Wen-yuan GAO
;
Lu-lu YAN
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; pathology; Animals; Antineoplastic Agents, Phytogenic; pharmacology; Cell Line, Tumor; Cell Proliferation; drug effects; Glycosides; chemistry; isolation & purification; pharmacology; Liliaceae; chemistry; Lung Neoplasms; pathology; Mice; Molecular Structure; Plants, Medicinal; chemistry; Rhizome; chemistry; Saponins; chemistry; isolation & purification; pharmacology
- From: China Journal of Chinese Materia Medica 2007;32(14):1425-1428
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the anti-tumor active constituents from the rhizome of Paris polyphylla var. yunnanensis.
METHODThe compounds were isolated by column chromatography with silica gel, and purified by Sephadex LH-20 columu chromafography and reverse-phase preparative, HPLC. The structures were identified by spectroscopic methods. The anti-tumor experiment in vitro, the MTT, was used to screen constituents of P. polyphalla var. yunnanensis.
RESULTSix compounds were obtained and their structures were identified as diosgenin-3-O-alpha-L-arabinofuranosyl (1-->4) -beta-D-glycopyranoside (1), pennogenin-3-O-alpha-L-arabino-furanosyl (1-->4)-beta-D-glycopyranoside (2), isorhamn etin-3-O-beta-D-glycopyranoside (3), ethyl-alpha-D-fructofuranoside (4), pennogenin-3-O-alpha-L-rhamnopyranosyl (1-->4)-[alpha-L-rhamnopyranosyl (1-->2)]-beta-D-glycopyranoside (5) and pennogenin-3-O-alpha-L-rhamnopyranosyl (1-->4)-alpha-L-rhamnopyranosyl (1-->4)-[alpha-L-rhamnopyranosyl (1-->2)]-beta-D-glycopyranoside (6).
CONCLUSIONCompounds 1-4 were isolated from this plant for the first time, compounds 3 and 4 was firstly isolated from genus Paris, compound 5 was firstly isolated from the rhizome of this plant. The pharmacological results showed that compounds 1-3, 5 and 6 showed certain inhibition, especially, the activities of compound 5 and 6 were the most significant.
